AAKP Patient Impact Statement: FDA APPROVAL OF THIRD VACCINE DOSE FOR KIDNEY TRANSPLANT PATIENTS
WASHINGTON, D.C. – “Kidney transplant patients, based on the lifetime immunosuppressive medications they must take to stay alive, remain at severe risk of catastrophic illness and death due to COVID-19. The American Association of Kidney Patients (AAKP) thanks the U.S. Food and Drug Administration (FDA) for incorporating the unique insights…